Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial

Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial

Neurite outgrowth inhibitor A (Nogo-A) is thought to have a role in the pathophysiology of amyotrophic lateral sclerosis (ALS). A monoclonal antibody against Nogo-A showed a positive effect in the SOD1(G93A) mouse model of ALS, and a humanised form of this antibody (ozanezumab) was well tolerated in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Lancet Neurology 2017-03, Vol.16 (3), p.208-216
Hauptverfasser: Meininger, Vincent, Genge, Angela, van den Berg, Leonard H, Robberecht, Wim, Ludolph, Albert, Chio, Adriano, Kim, Seung H, Leigh, P. Nigel, Kiernan, Matthew C, Shefner, Jeremy M, Desnuelle, Claude, Morrison, Karen E, Petri, Susanne, Boswell, Diane, Temple, Jane, Mohindra, Rajat, Davies, Matt, Bullman, Jonathan, Rees, Paul, Lavrov, Arseniy
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Neurite outgrowth inhibitor A (Nogo-A) is thought to have a role in the pathophysiology of amyotrophic lateral sclerosis (ALS). A monoclonal antibody against Nogo-A showed a positive effect in the SOD1(G93A) mouse model of ALS, and a humanised form of this antibody (ozanezumab) was well tolerated in a first-in-human trial. Therefore, we aimed to assess the safety and efficacy of ozanezumab in patients with ALS.
ISSN:1474-4422